Akademska digitalna zbirka SLovenije - logo
E-resources
Peer reviewed Open access
  • The receptor of the colony-...
    Valero, Juan Garcia; Matas-Céspedes, Alba; Arenas, Fabián; Rodriguez, Vanina; Carreras, Joaquim; Serrat, Neus; Guerrero-Hernández, Martina; Yahiaoui, Anella; Balagué, Olga; Martin, Silvia; Capdevila, Cristina; Hernández, Lluis; Magnano, Laura; Rivas-Delgado, Alfredo; Tannheimer, Stacey; Cid, Maria C; Campo, Elías; López-Guillermo, Armando; Colomer, Dolors; Pérez-Galán, Patricia

    Leukemia, 09/2021, Volume: 35, Issue: 9
    Journal Article

    Microenvironment contributes to follicular lymphoma (FL) pathogenesis and impacts survival with macrophages playing a controversial role. In the present study, using FL primary samples and HK follicular dendritic cells (FDC) to mimic the germinal center, together with mouse models, we have analyzed the three-way crosstalk of FL-FDC-macrophages and derived therapeutic opportunities. Ex vivo primary FL-FDC co-cultures (n = 19) and in vivo mouse co-xenografts demonstrated that FL-FDC crosstalk favors tumor growth and, via the secretion of CCL2 and CSF-1, promotes monocyte recruitment, differentiation, and polarization towards an M2-like protumoral phenotype. Moreover, FL-M2 co-cultures displayed enhanced angiogenesis, dissemination, and immunosuppression. Analysis of the CSF-1/CSF-1R pathway uncovered that CSF-1 was significantly higher in serum from grade 3A FL patients, and that high CSF-1R expression in FL biopsies correlated with grade 3A, reduced overall survival and risk of transformation. Furthermore, CSF-1R inhibition with pexidartinib (PLX3397) preferentially affected M2-macrophage viability and polarization program disrupting FL-M2 positive crosstalk. In vivo CSF1-R inhibition caused M2 reduction and repolarization towards M1 macrophages and antitumor effect cooperating with anti-CD20 rituximab. In summary, these results support the role of macrophages in FL pathogenesis and indicate that CSF-1R may be a relevant prognostic factor and a novel therapeutic target cooperating with anti-CD20 immunotherapy.